Your browser doesn't support javascript.
loading
Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
Laquer, Vivian; Parra, Viviana; Lacour, Jean-Philippe; Takahashi, Hidetoshi; Knorr, Jack; Okragly, Angela J; James, Douglas E; Sims, Jonathan T; Chang, Ching-Yun; Chao, Jeannie; Klekotka, Paul.
Afiliação
  • Laquer V; First OC Dermatology, Fountain Valley, CA, USA.
  • Parra V; Área de Dermatología, National University of Cuyo, Mendoza, Argentina.
  • Lacour JP; Department of Dermatology, University of Nice-Côte d'Azur, Nice, France.
  • Takahashi H; Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan.
  • Knorr J; Eli Lilly and Company, Indianapolis, IN, USA.
  • Okragly AJ; Eli Lilly and Company, Indianapolis, IN, USA.
  • James DE; Eli Lilly and Company, Indianapolis, IN, USA.
  • Sims JT; Eli Lilly and Company, Indianapolis, IN, USA.
  • Chang CY; Eli Lilly and Company, Indianapolis, IN, USA.
  • Chao J; Eli Lilly and Company, Indianapolis, IN, USA.
  • Klekotka P; Eli Lilly and Company, Indianapolis, IN, USA.
Br J Dermatol ; 187(4): 599-602, 2022 10.
Article em En | MEDLINE | ID: mdl-35481678
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica Idioma: En Ano de publicação: 2022 Tipo de documento: Article